News

The AZ-007 Phase I clinical trial is projected to enroll approximately 40 healthy volunteers at a single US clinical center. The purpose of this trial is to assess

The company said that the study evaluated the efficacy, safety and tolerability of an innovative, proprietary, 28mg memantine extended-release, once-daily formulation compared to placebo in outpatients with moderate

MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. According to GeneGo, GlaxoSmithKline (GSK) will also use the platform as a repository of all types

Daniel Yarosh, president of AGI Dermatics, said: “The new products include our first retinol-based formulas and reinforce our commitment to harnessing the power of the industry’s most effective

The agreement will utilize DSM’s commercial facilities in Greenville, North Carolina. Howard Raff, COO of APT Pharmaceuticals, said: “DSM has a superior reputation in sterile manufacturing, experience with

This follows a favourable response from FDA, allowing Forest to initiate an additional Phase II study in COPD for Oglemilast (GRC 3886). Glenmark and Forest Labs are working

The BLA is based on data from more than 2,367 patients and includes three multi-center, placebo-controlled Phase III trials. In these studies Cimzia, given with methotrexate, was shown

The Matrix (A Phase IIb Study of GAM501 in the treatment of diabetic ulcers in the lower extremities) trial is a randomized, double-blind, placebo-controlled, comparator arm (standard of

Lpath will soon begin dosing patients in the first clinical study ever performed involving an antibody that inhibits a bioactive lipid. Lpath plans a multi-center Phase I open-label,